Posted by Michael Wonder on 06 Jun 2022
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
6 June 2022 - Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients
GSK today announced that the US FDA has approved Priorix (measles, mumps and rubella vaccine, live) for active immunisation for the prevention of measles, mumps and rubella in individuals 12 months of age and older.
